PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32410477-1	2020	Objective: This study aims to investigate the beneficial effects of 17beta-estradiol supplementation on the function of osteoblastic cells through the Sirtuin-1/nuclear transcription factor-kappaB/matrix metalloproteinase-8 (Sirt1/NF-kappaB/MMP-8) pathway.Methods: Mouse primary osteoblasts were obtained from neonatal mouse calvaria, and the cells were treated with or without 17beta-estradiol.	Estradiol	68-84	matrix metallopeptidase 8	Mus musculus	241-246	
32410477-0	2020	17beta-Estradiol improves osteoblastic cell function through the Sirt1/NF-kappaB/MMP-8 pathway.	Estradiol	0-16	matrix metallopeptidase 8	Mus musculus	81-86	
32410477-5	2020	In addition, 17beta-estradiol supplement activated ERalpha and Sirt1 expression and inhibited NF-kappaB and MMP-8 expression.	Estradiol	13-29	matrix metallopeptidase 8	Mus musculus	108-113	
32410477-6	2020	Moreover, these effects induced by 17beta-estradiol were reversed by knockdown of Sirt1 in mouse primary osteoblasts.Conclusion: 17beta-Estradiol replacement therapy may treat postmenopausal osteoporosis by improving osteoblastic cell function via the Sirt1/NF-kappaB/MMP-8 pathway.	Estradiol	35-51	matrix metallopeptidase 8	Mus musculus	268-273	
32410477-6	2020	Moreover, these effects induced by 17beta-estradiol were reversed by knockdown of Sirt1 in mouse primary osteoblasts.Conclusion: 17beta-Estradiol replacement therapy may treat postmenopausal osteoporosis by improving osteoblastic cell function via the Sirt1/NF-kappaB/MMP-8 pathway.	Estradiol	129-145	matrix metallopeptidase 8	Mus musculus	268-273